Last10K.com

Tabula Rasa Healthcare, Inc. (TRHC) SEC Filing 10-Q Quarterly report for the period ending Tuesday, June 30, 2020

Tabula Rasa Healthcare, Inc.

CIK: 1651561 Ticker: TRHC

Exhibit 99.1

Tabula Rasa HealthCare Reports Second Quarter 2020 Results

MOORESTOWN, N.J., August 4, 2020 (GLOBE NEWSWIRE) -- Tabula Rasa HealthCare, Inc. (“TRHC”) (NASDAQ:TRHC), a healthcare technology company advancing the field of medication safety, today reported financial results for the second quarter ended June 30, 2020.

Second Quarter 2020 Highlights

Total revenue of $76.8 million, which is within our guidance range of $76.0 million to $81.0 million for the second quarter of 2020, was up 1% as compared to the second quarter of 2019.
Non-GAAP Adjusted EBITDA of $7.1 million, which is within our guidance range of $7.0 million to $9.0 million for the second quarter of 2020, declined as compared to $13.7 million for the same period in 2019, which marked a record high for any quarter in company history.
Non-GAAP Adjusted Diluted EPS declined to $0.07 as compared to $0.35 during the same period in 2019.
CareVention HealthCare revenue increased 13% to $50.5 million, driven by organic PACE product revenue growth.
MedWise HealthCare revenue decreased 16% to $26.4 million, driven by the expected decline in medication safety services, partially offset by software subscriptions growth on a reported basis of 14%. Medication safety services increased 10% on a sequential basis as compared to the first quarter of 2020, driven by strong growth in the number of total clinical interventions performed.
Due to COVID-19, bookings were relatively flat as compared to the second quarter of 2019, driven by a decline within our CareVention HealthCare segment which offset continued growth within our MedWise HealthCare segment, led by another strong quarter of sales to health plans. Notable new contractual relationships include a national retail chain, a large supermarket chain and a senior-focused network of primary care centers. In addition to these new bookings, we entered into a multi-year contract renewal with one of our top five PACE clients in terms of membership and revenue.
Our overall sales pipeline has continued to grow, driven by our two largest end-markets (PACE and health plans), which combined are 73% higher as of July 1, 2020 as compared to January 1, 2020.

“I am pleased with our second quarter performance as our revenue and Adjusted EBITDA results were within our guidance range despite COVID-19 related challenges that became significantly more pronounced in May and June across our primary target markets. Our PACE census trends have shown continued improvement during June, July and August but our overall enrollment growth remains below historical levels, largely due to slower-than-expected growth within our clients’ existing PACE centers as they continue to deal with the pandemic. In addition, following our record sales in the first quarter of 2020, our MedWise HealthCare segment experienced delays in the timing of implementations and closing new business during the second quarter. We remain encouraged by positive signs within our CareVention HealthCare segment, continued healthy growth in our sales pipeline, and our efforts to broaden the adoption of our medication science as evidenced by the major launch of MedWise for our PrescribeWellness community pharmacists,” said Calvin H. Knowlton, PhD, TRHC’s Chief Executive Officer, Chairman and Founder.

Second Quarter 2020 Results

All comparisons, unless otherwise noted, are to the three months ended June 30, 2019.

Total revenue - Total revenue of $76.8 million was up 1% as compared to $76.3 million. Total revenue included product revenue of $39.4 million, an increase of 18%, and solutions (i.e. software and services) revenue of $37.5 million, a decrease of 13%. On a sequential basis compared to the first quarter of 2020, total revenue increased 6%. Product revenue of $39.4 million includes $0.4 million related to the initial sales of COVID-19 test kits through our PrescribeWellness pharmacy network.


The following information was filed by Tabula Rasa Healthcare, Inc. (TRHC) on Tuesday, August 4, 2020 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-Q Quarterly Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one quarter to another to evaluate Tabula Rasa Healthcare, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Tabula Rasa Healthcare, Inc..

Continue

Assess how Tabula Rasa Healthcare, Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Tabula Rasa Healthcare, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2020 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

SEC Filing Tools

Financial Statements, Disclosures and Schedules

Inside this 10-Q Quarterly Report

Document And Entity Information
Consolidated Balance Sheets
Consolidated Balance Sheets (Parenthetical)
Consolidated Statements Of Cash Flows
Consolidated Statements Of Cash Flows (Parenthetical)
Consolidated Statements Of Operations
Consolidated Statements Of Stockholders' Equity
Accrued Expenses And Other Liabilities
Accrued Expenses And Other Liabilities (Details)
Accrued Expenses And Other Liabilities (Tables)
Acquisitions
Acquisitions (Tables)
Acquisitions - Doseme (Details)
Acquisitions - Prescribe Wellness (Details)
Acquisitions - Pro Forma (Unaudited) (Details)
Basis Of Presentation, Summary Of Significant Accounting Policies, And Recent Accounting Pronouncements
Basis Of Presentation, Summary Of Significant Accounting Policies, And Recent Accounting Pronouncements (Policies)
Basis Of Presentation, Summary Of Significant Accounting Policies, And Recent Accounting Pronouncements - Basis Of Presentation (Details)
Commitments And Contingencies
Commitments And Contingencies - Vendor Purchase Agreements (Details)
Fair Value Measurements
Fair Value Measurements (Tables)
Fair Value Measurements - Contingent Consideration (Details)
Fair Value Measurements - Contingent Consideration Rollforward (Details)
Fair Value Measurements - Financial Instruments (Details)
Fair Value Measurements - Liabilities (Details)
Goodwill And Intangible Assets
Goodwill And Intangible Assets (Tables)
Goodwill And Intangible Assets - Amortization (Details)
Goodwill And Intangible Assets - Goodwill (Details)
Goodwill And Intangible Assets - Intangible Assets (Details)
Income Taxes
Income Taxes (Details)
Lines Of Credit And Long-Term Debt
Lines Of Credit And Long-Term Debt (Tables)
Lines Of Credit And Long-Term Debt - Convertible Note Hedge And Warrant Transactions (Details)
Lines Of Credit And Long-Term Debt - Convertible Senior Subordinated Notes (Details)
Lines Of Credit And Long-Term Debt - Lines Of Credit (Details)
Lines Of Credit And Long-Term Debt - Long-Term Debt (Details)
Nature Of Business
Nature Of Business (Details)
Net (Loss) Income Per Share - Anti-Dilutive Securities (Details)
Net Loss Per Share
Net Loss Per Share (Tables)
Net Loss Per Share - Eps (Details)
Property And Equipment
Property And Equipment (Details)
Revenue
Revenue (Tables)
Revenue - Change In Contract Balances (Details)
Revenue - Contract Balances (Details)
Revenue - Disaggregation (Details)
Revenue - General (Details)
Segment Reporting
Segment Reporting (Tables)
Segment Reporting - Reconciliation Of Net Loss To Adjusted Ebitda (Details)
Segment Reporting - Revenue And Ebitda (Details)
Software Development Costs
Software Development Costs (Details)
Software Development Costs (Tables)
Stock-Based Compensation
Stock-Based Compensation (Tables)
Stock-Based Compensation - Expense (Details)
Stock-Based Compensation - Options Activity (Details)
Stock-Based Compensation - Options Valuation (Details)
Stock-Based Compensation - Other Stock Awards (Details)
Stock-Based Compensation - Performance Based Equity Awards (Details)
Stock-Based Compensation - Plans (Details)
Stock-Based Compensation - Restricted Common Stock (Details)
Stockholders' Equity
Stockholders' Equity - Warrants (Details)
Ticker: TRHC
CIK: 1651561
Form Type: 10-Q Quarterly Report
Accession Number: 0001558370-20-009704
Submitted to the SEC: Thu Aug 06 2020 4:57:01 PM EST
Accepted by the SEC: Thu Aug 06 2020
Period: Tuesday, June 30, 2020
Industry: Business Services

External Resources:
Stock Quote
Social Media
SEC.gov

Bookmark the Permalink:
https://last10k.com/sec-filings/trhc/0001558370-20-009704.htm